If so, then Acorda Therapeutics, Inc. would like you to know that on January 30, 2009, they submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Fampridine-SR, a novel therapy developed to “improve walking ability” in people with multiple sclerosis.
Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine or 4-AP). In laboratory studies, fampridine has been found to improve impulse conduction in...
Nadja is a teacher, a refashionista of clothing, and a passionate blogger. But more so she is a compassionate and caring friend. She... Read more »
There are 400,000 MSers in the U.S. In 2004, approximately 45% of them were over 55. A Population Tsunami is predicted over the next four... Read more »
Suicide and MS have had a long relationship. This is Suicide Prevention Week (Sept. 5-11), and Sept. 10 is Suicide Prevention Day.... Read more »
It was during my limbo days prior to my official MS diagnosis that I stumbled upon a charismatic lady named Diane J. Standiford. I was... Read more »
Living well with MS can't exclude exercise.There was a time when my daily routine included walking for miles and playful activities like... Read more »
What is optic neuritis? According to ADAM Medical Encyclopedia, optic neuritis is "inflammation of the optic nerve; it may cause sudden, reduced vision in the affected eye." Though the exact cause is unknown, sudden swelling of the optic nerve...
Featuring Content From:
By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.
